Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Foamix Pharmaceuticals

Thumbnail
February 21, 2020

Upcoming events – Filgotinib's ulcerative colitis data and serlopitant takes on pruritus

Gilead and Galapagos's filgotinib might not be a match for Rinvoq in ulcerative colitis, while Menlo needs to prove serlopitant works after previous setbacks.

Thumbnail
November 01, 2019

US FDA approval tracker: October

Article image
Vantage logo
September 27, 2019

Go or no go? Novartis eyes a big new growth driver

The biggest approval decision in October will involve Novartis’s eye asset Beovu, while Biogen and Alkermes face a key verdict in MS.

Article image
Vantage logo
September 12, 2018

Perseverance pays off for Foamix

Vantage logo
March 05, 2018

Dermira in a spot of bother after acne failure

Vantage logo
November 24, 2017

Upcoming events – Another SGLT2 approval due and stem cell data for Mesoblast

Article image
Vantage logo
July 10, 2017

Strong small cap performance drives second-quarter gains

Vantage logo
April 06, 2017

Mid-cap biopharma stocks pick up in the first quarter

Vantage logo
September 28, 2016

Interview – Foamix spots dermatology opportunity

Vantage logo
September 16, 2016

Snippet roundup: Wins for AcelRx, Foamix and SGLT2 developers.

Vantage logo
October 02, 2014

IPOs surge in Q3 as investor enthusiasm shows no sign of waning

We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.